MassBio Annual Meeting & Vendor Expo
Tuesday, March 30 – Wednesday, March 31 2010
Agenda subject to change, please visit website for regular updates
Tuesday, March 30th
11 am Registration Opens
12 - 1:30 pm Luncheon in Trade Show Hall
1:30 - 2 pm Welcome, MassBio Annual Business
2- 3 pm Opening Address from George M. Whitesides, Woodford L. and Ann A. Flowers University Professor, Harvard University
Introduction by Una S. Ryan, O.B.E., Ph.D., President & CEO, Diagnostics for All
3:10 - 4:10 pm Panel Discussion -Academia, Biotech and Pharma Collaborations
Collaboration and partnering are the backbone of advancing novel therapies and diagnostics through the development pathway, starting at the very early stage and into clinical development. At the early stage, academic collaborations with industry drive "context" around a drug asset. New research tools, mouse models and pathway work provide detailed annotation around drug-target interaction, thereby improving predictions around safety and efficacy. Collaborations among industry partners drives translation of early stage discoveries through clinical development and into real products that improve patient lives.
This discussion will focus on issues including:
- What are the essential elements of a successful collaboration?
- How does collaboration typically work?
- Which types of collaborations are most successful? Why?
David Altshuler M.D., PhD, Deputy Director and Chief Academic Officer, Broad Institute of Harvard and MIT and Professor of Genetics and of Medicine, Harvard Medical School and Massachusetts General Hospital
David R. Cox, M.D., Ph.D., Senior Vice President and CSO, Applied Quantitative Genotherapeutics, Pfizer Inc.
Howard Mayer, MD, CMO, EMD Serono
Timothy Coetzee, President, FastForward
Susanna High, Vice President, Business Planning and Program Management, Alnylam Pharmaceuticals, Inc.
Charles Wilson, Vice President, Global Head of Strategic Alliances, Novartis Institutes for BioMedical Research, Inc.
Jose-Carlos Gutierrez-Ramos, Ph.D., Senior Vice President and head of the BioTherapeutics Research Group, Pfizer, Inc. (moderator)
4:15 - 5 pm Keynote - Impact of Human Genetics on Treating Complex Diseases
Speaker: David Altshuler, Broad Institute
Clinical endocrinologist and human geneticist David Altshuler is a founding member of the Broad Institute. He serves as director of the Broad's program in Medical and Population Genetics, as well as the Institute's first Chief Academic Officer/Deputy Director.
5:15 - 6 pm Closing Plenary Discussion & Concert: Longwood Symphony Orchestra featuring Leonard Zon, M.D.
Longwood Symphony Orchestra is a Boston-based ensemble whose musicians are also medical professionals dedicated to Healing the Community through Music.
6 - 7:30 pm Reception in Innovation 2010 Vendor Expo Hall
Wednesday, March 31st
8:00 am Breakfast in Innovation 2010 Vendor Expo Hall
8:45 - 9:45 am Fireside Chat with CEOs
Boston has three well-known biotechnology success stories, Biogen Idec, Genzyme, and Millennium: The Takeda Oncology Company. Over two decades these three companies have defied the odds of evolving from small start-up companies with very humble beginnings and have grown to be fully integrated pharmaceutical companies. As each of these companies have experienced certain growing pains during these past decades, they now face new challenges as they metamorphose into their new role, global pharmaceutical companies. Massachusetts' own CEOs, led by Deborah Dunsire, will discuss the challenges each company has as they have stepped into the global marketplace, and how they managed through difficult periods. These are lessons learned by having lived through them-lessons all companies should mind!
James C. Mullen, CEO & President, Biogen Idec
Deborah Dunsire, President & CEO, Millennium: The Takeda Oncology Company (moderator)
Henri Termeer, Chairman, President and CEO, Genzyme Corporation
10- 11 am Concurrent Break Out Sessions
Session I: Diseases of Aging
This panel focuses on how collaborations among industry (biotech and pharma) and academia have led to remarkable insights into age-related disorders and the development of novel therapies directed towards improving [gain of function] and improved quality of life. This panel will highlight the reciprocal contributions of collaborators in advancing these therapies forward and how it will advance patient care.
Kees Been, President and Chief Executive Officer, EnVivo Pharmaceuticals, Inc.
Brian S. Bronk, Vice President of Chemistry, Satori Pharmaceuticals Inc.
Ole Isacson, Professor, M.D., Ph.D., Director of Center for Neuroregeneration Research, McLean Hospital/Harvard Medical School
Joseph F. Coughlin, Director, AgeLab, Massachusetts Institute of Technology
Sathapana (Sam) Kongsamut, Ph.D., Unit Development Office, TSU Aging,
Moderator: Dianne Bourque, Associate, Health Law Section, Mintz Levin
Session II: RNA Therapeutics
The discovery of RNAi and its follow-on applications in therapeutics is over twenty five years in the making. Starting as experimental observation and now as a potential treatment modality, RNAi has truly translated from the bench and into the clinic (and hopefully soon to the bedside). This panel will discuss the challenges of bringing innovation out of the lab and into the clinic, and how leveraging partnerships catalyzes this process.
Arthur M. Krieg, MD, Chief Scientific Officer, Pfizer's Research Technology Center
Anastasia Khvorova, PhD, CSO, RXi Pharmaceuticals Corporation
Stuart Pollard, Ph.D., Vice Presdient, Scientific and Business Strategy, Alnylam Pharmaceuticals, Inc.
Ian Tzeng, Vice President, L.E.K. Consulting (moderator)
Sponsored by: L.E.K. Consulting
11:10 am - 12:10 pm Concurrent Break Out Sessions
Session I: Novel Chemistry
Novel chemistry presents an exciting array of new technologies that range from catalyzing programmed synthesis of new molecular entities, and increasing the binding affinities - in this case covalently- to silence targets necessary to disease etiology, to "stapling" proteins to modulate protein-protein interactions. These next generation technologies offer some of the most exciting technologies to arise out academia and industry.
Juswinder Singh, PhD, Co-Founder and Chief Scientific Officer, Avila Therapeutics, Inc.
Nick K. Terrett, Ph.D., Chief Scientific Officer, Ensemble Discovery
Louis Plamondon, Ph.D., Sr. Vice President, Chemistry, TetraPhase Pharmaceuticals, Inc.
Janet Wolfe, Ph.D., Founder and President, Wolfe Laboratories (Moderator)
Session II: Biotherapeutics
Increasingly, biotherapeutics are seen as the next big opportunity for therapeutic treatment. Cost advantages in downstream manufacturing from new products like ready-to-use bioreactors to pre-packed chromatography columns, new improvements to adjuvants reducing antigen dose for vaccines, and new biotherapeutic structures like vaccibodies (hybrid comprising vaccine and antibody) offer alternatives to drug manufacturers.
Tariq Ghayur, Ph.D., Senior Principle Scientist and Research Fellow, Abbott Laboratories
Ulrik B. Nielsen, Ph.D., Chief Scientific Officer, Merrimack Pharmaceuticals
Andrew E. Nixon, Ph.D., Vice President, Lead Discovery & Biochemistry, Discovery Research, Dyax Corp.
Jeff Hanke, SVP Research and Global Head Biotherapeutics Research, Boehringer Ingelheim (moderator)
12:15 - 1:45 pm Awards luncheon featuring:
MassBio Innovative Leadership Award
Michael W. Bonney, President & CEO, Cubist Pharmaceuticals
MassBioEd Innovative School of the Year
Bellingham High School
2 - 3 pm Fireside Chat with the Nobel Laureates
Richard Roberts, Ph.D., Chief Scientific Officer, New England Biolabs, Inc.
Phillip A. Sharp, Ph.D., Institute Professor, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
Scott Kirsner, Innovation Economy columnist, Boston Globe (moderator)
3:10 - 4:10 pm Panel Discussion: Regenerative Medicine
Brock Reeve, Executive Director, Harvard Stem Cell Institute (moderator)
David Mooney, PhD, Associate Dean for Chemical/Biological Sciences and Engineering, Harvard School of Engineering and Applied Sciences
Lee Rubin, PhD, Director of Translational Medicine, Harvard Stem Cell Institute
Leonard Zon, MD, Director Children's Hospital Boston Stem Cell Program, Children's Hospital Boston
Ruth McKernan, Regenerative Medicine Chief Scientific Officer, Pfizer
4:20 - 5:20 pm Panel Discussion- Re-Apportioning Risk Among Stakeholders in the Pharmaceutical Value Chain - Continuing to Support Innovation in a Difficult Financial Climate
Traditional financial tools such as venture capital and the IPO market are no longer able to support novel biomedical R&D. This panel will explore new ways to finance innovation in the current financial climate, both within the for-profit as well as academic environment. For example, the growing model of financing R&D outside the pharma/biotech company will be explained. In addition, creative mechanisms for underwriting the support of translational medicine within the academic medical center will be described in detail.
Michael Lytton, EVP, Corporate Business Development, Biogen Idec (moderator)
Mark A. Goldsmith, M.D., Ph.D., President and Chief Executive Officer, Constellation Pharmaceuticals
Dr. Neal Goodwin, Founding Director, Jackson Laboratory (JAX) Cancer Services Laboratory
Dr. Raju Kucherlapati, Paul C. Cabot Professor of Genetics, Harvard Medical School
Tim Surgenor, Red Sky Partners
5:30 pm Adjourn